Información del artículo
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 2010; 50:126-42.
[2]
Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol Biosyst. 2010; 6:305-15.
[3]
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 2008; 51:256-60.
[4]
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101:714-9.
[5]
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-8.
[6]
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937-44.
[7]
Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study [abstract 3998]. Circulation. 2008; 118:S815.
[8]
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet. 2009; 374:989-97.
[9]
Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial [abstract 3999]. Circulation. 2008; 118:S815.
[10]
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363:1909-17.
[11]
Open database: Clinicaltrials.gov [Base de datos en Internet]. Cogentus Pharmaceuticals. Clopidogrel and the optimization of gastrointestinal events (COGENT-1). [citado 01-02-2011]. Disponible en: http://www.clinicaltrials.gov.
[12]
Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2008; 103:104-10.
[13]
Antibiotics prophylaxis in acute necrotizing pancreatitis: an update. Am J Gastroenterol. 2010; 105:705-7.
[14]
American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40:2945-8.
[15]
Product Information. Teva Neuroscience, 2010 [consultado 29 Mar 2010]. Disponible en: http://www.azilect.com.
[16]
Product Information. Food and Drug Administration (FDA), 2009 [consultado 29 Mar 2010]. Disponible en: http://www.accessdata.fda.gov/.
[17]
Chen JJ, Adar L, Goren T, Nissim S, Yoni W. A clinical pharmacology study to determine the selective and non-selective doses of rasagiline, a monoamine oxidase type B inhibitor; [Poster 4-092] 44th ASHP Midyear Clinical Meeting Des 6-10, Las Vegas [consultado 29 Mar 2010]. Disponible en: www.cmcgc.com/media/handouts.
[18]
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural Transm Suppl. 1988; 26:31-56.
[19]
Teva Pharma. Ficha técnica del producto, 2009.
[20]
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008; 299:185-93.
[21]
A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006; 163:2072-9.
[22]
Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001; 345:1359-67.
[23]
Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008; 300:933-44.
[24]
Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360:1283-97.
[25]
Limits to lipid in the literature and lab: what we know, what we don’t know. Anesth Analg. 2009; 108:1062-4.
[26]
Weinberg G. Lipid rescue [consultado 29 Mar 2010]. Disponible en: www.lipidrescue.org/.
[27]
Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. J Trauma. 2008; 65:34-41.
[28]
Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004; 291:1753-62.
[29]
The association between delirium and cognitive decline: a review of the empirical literature. Neuropsychol Rev. 2004; 14:87-98.
[30]
Multidisciplinary management of sedation and analgesia in critical care. Semin Respir Crit Care Med. 2001; 22:211-6.
[31]
Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med. 2009; 37:177-83.
[32]
Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006; 104:21-6.
[33]
A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999; 340:669-76.
[34]
Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals. Crit Care Med. 2009; 37:825-32.
[35]
Confusion assessment method for diagnosing delirium in ICU patients (CAM-ICU): Cultural adaptation and validation of the Spanish version. Med Intensiva. 2010; 34:4-13.
[36]
Versión en español del método para la evaluación de la confusión en cuidados intensivos, estudio piloto de validación. Med Intensiva. 2010; 34:14-21.
[37]
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010; 38:419-27.
[38]
Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004; 30:444-9.
[39]
A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004; 45:297-301.
[40]
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med. 2010; 38:428-37.
[41]
Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009; 301:489-99.
[42]
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009; 13:R75.
[43]
Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008; 42:1703-5.
